| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4466 | Ro5234444 | Orally active chemokine receptor CCR2 antagonist preventing glomerulosclerosis and renal failure in type 2 diabetes |
|
| DCC4467 | Ro5527239 | Novel potent, orally available GPBAR1 agonist |
|
| DCC4468 | Ro-57-bpyne | Novel γ-secretase modulator photoaffinity probe, identifying distinct allosteric binding sites on presenilin that can be exploited to reduce levels of pathogenic Aβ species |
|
| DCC4469 | Ro6800020 | Potent γ-secretase modulator (GSM) |
|
| DCC4470 | Ro6842262 | Novel potent and selectve LPA1 antagonist, attenuating NHLF human lung fibroblast cell proliferation and contraction in vitro, reducing plasma histamine levels in mouse LPA-challenge model |
|
| DCC4471 | Ro7101556 | Novel potent γ-secretase modulator (GSM) with high solubility, balanced lipophilicity, and showing no phototoxicity and PIK4CB side bing activity |
|
| DCC4472 | Robalzotan | Selective antagonist at the 5-HT1A receptor |
|
| DCC4473 | Rocepafant | Platelet-activating factor (PAF-R) antagonist, selectively for intracellular PAF binding sites |
|
| DCC4474 | Rockii-in-di | Novel potent competitive inhibitor of Rho-associated coiled-coil-containing protein kinase 2 (ROCKII) |
|
| DCC4475 | Rock-in-(r)14f | Novel potent ROCK inhibitor |
|
| DCC4476 | Rock-in-32 | Potent Rho--kinase (ROCK) inhibitor |
|
| DCC4477 | Rock-in-d1 | Novel potent and selective ROCK inhibitor |
|
| DCC4478 | Rock-in-d2 | Novel potent and selective ROCK inhibitor |
|
| DCC4479 | Rock-in-d3 | Novel potent and selective ROCK inhibitor |
|
| DCC4480 | Rohitukine | Anti-cancer agent, acting through gastrin antagonism and H /K -ATPase inhibition, modulating apoptosis pathways, antidyslipidemic, antiadipogenic, gastroprotective, antifertility, and antileishmanial |
|
| DCC4481 | Ronifibrate | Lipid modifying agent; Antihyperlipidemic and antiarteriosclerotic |
|
| DCC4482 | Rooperol | Novel p38α kinase inhibitor; Antioxidant |
|
| DCC4483 | Ropizine | Allosteric modulator of dextromethorphan binding to high-affinity sigma receptors |
|
| DCC4484 | Ror Modulator I | The first potent inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt |
|
| DCC4485 | Rorgammat Agonist 8-074 | Novel potent and selective RORγt agonist, showing robust antitumor efficacy in syngeneic tumor models and improving the efficacy of anti‑PD‑1 in a murine lung cancer model |
|
| DCC4486 | Rorgammat Inhibitor I | Novel RORgammaT inhibitor |
|
| DCC4487 | Rorγt Agonist | Novel RORγt agonist |
|
| DCC4488 | Rorγt-inverse-agonist-1j | Novel potent RORγt inverse agonist |
|
| DCC4489 | Rosma-18-d6 | Novel potent and selective CB2 probe (Ki for CB2: 0.8 nM and >12000 selectivity over CB1) |
|
| DCC4490 | Ros-modulator-3b | Novel P2X3 antagonist |
|
| DCC4491 | Rostaporfin | Photosensitiser for the treatment of age-related macular degeneration |
|
| DCC4492 | Rovafovir | Novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor |
|
| DCC4493 | Rovafovir Etalafenamide | Prodrug of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148 |
|
| DCC4494 | Roxatidine Acetate | Specific and competitive H2 receptor antagonist |
|
| DCC4495 | Rp-001 Hydrochloride | Potent agonist of S1P1 receptors |
|
